

ISOENERGY CORNERSTONE \$4.36M STRATEGIC PLACEMENT



Highlights:

- Orpheus Uranium receives firm commitments to raise \$4.36M at \$0.062 per share
- IsoEnergy Ltd. (TSE.ISO) (NYSE.ISOU), a globally diversified uranium company with a Market Capitalisation of ~ \$1B (AUD), cornerstone the placement with a \$1.5M investment
- Placement funds to advance South Australian, Northern Territory and Western Australian projects, whilst supporting further development of the portfolio

Orpheus Uranium Limited (ASX: ORP) (“Orpheus” or “the Company”) is pleased to announce that it has received firm commitments for a share placement of approximately 70.4 million new fully paid ordinary shares at \$0.062 per share (“Placement”), raising \$4.36 million (before costs).

The Placement will be completed under the Company’s existing placement capacity under ASX Listing Rules 7.1 (42,254,569 shares) and 7.1A (28,169,712 shares). The Placement proceeds will be used to fund exploration of the Company’s uranium projects in South Australia, Northern Territory, and Western Australia, in addition to developing Orpheus’ geologically prospective project portfolio, general working capital and the Placement costs.

The Placement will comprise the issue of approximately 70.4 million new fully paid ordinary shares (“New Shares”) at an issue price of A\$0.062 per share, which represents a:

- 2.9% discount to the 15-day VWAP price (up to and including 30th January 2026) of A\$0.064; and is
- Approximate to the 20-day VWAP price (up to and including 30th January 2026) of A\$0.062.

The New Shares will rank equally with the Company’s existing shares on issue. IsoEnergy Ltd. (“IsoEnergy” or “ISO”) will cornerstone the Placement, which is being extended to institutional, sophisticated, and professional investors who qualify under Section 708 of the Corporations Act.

Taylor Collison Limited is the Sole Lead Manager to the Placement. Taylor Collison will receive a fee of 2% of total proceeds and 6% on total proceeds excluding funds procured from IsoEnergy Limited. Taylor Collison will also receive approximately 4.3 million unlisted options, each with an exercise price equal to a 50% premium to the offer price and expiring three years from allotment, subject to shareholder approval.

“We welcome IsoEnergy as a strategic investor in Orpheus. Their decision to invest is a strong endorsement of the quality of our uranium portfolio, the significant progress we have made advancing our projects, and the technically strong and highly capable team we have built.”

IsoEnergy is recognised globally as a leader in the uranium sector, and their mission aligns well with Orpheus’ strategy of building a portfolio of assets at varying stages of development, providing short- and long-term leverage to exploration success and rising uranium prices. We look forward to growing our relationship with the IsoEnergy team as we continue to drive our exciting exploration program forward.”

- Orpheus Managing Director Clinton Dubieniecki

Indicative Timetable

The proposed key dates for the Placement are as follows:

<u>Event</u>	<u>Date</u>
Announcement of Placement	Wednesday, 04 February
Settlement of Placement Securities	Monday, 09 February
Allotment of Placement Securities	Tuesday, 10 February

* Note: Dates and times references are to Sydney Time (AEDT / 2026).

About IsoEnergy (TSE.ISO) (NYSE.ISOU)

IsoEnergy is a leading, globally diversified uranium company listed on the TSX in Canada and has a market capitalisation of approximately \$1B (AUD). It is currently exploring and developing its substantial uranium resources across Canada, the U.S., and Australia, providing near-, medium-, and long-term leverage to rising uranium prices.

IsoEnergy leads the placement as a cornerstone investor, committing A\$1.5M and taking a 6.87% stake in Orpheus Uranium.

-END-

This announcement was approved for release by the Board of Orpheus Uranium Limited.

For further information, please contact:

Clinton Dubieniecki

Managing Director & Chief Executive Officer

E. clinton@orpheusuranium.com

Richard Willson

Company Secretary

E. richard@orpheusuranium.com

About Orpheus Uranium

Orpheus Uranium Limited is an Australian Securities Exchange (ASX) listed exploration company exploring for uranium in South Australia and the Northern Territory, both jurisdictions which allow uranium exploration, mining and processing. More recently, Orpheus has extended tenure into Western Australia through the acquisition of the Oobagooma Uranium Project, a state that contains multiple known uranium deposits.

Forward Looking Statements

The written presentation may contain forward-looking statement regarding the outlook for the Company's interpretation, work programs, and financial results. These forward-looking statements generally can be identified by phrases such as "anticipates", "potential", "plans", "intends", "believes", "likely", "appears", "expects", "likely", "appears" or other words or phrases of similar impact. There is inherent risk and uncertainty in any forward-looking statements. Variance will occur and some could be materially different from management's opinion. Developments that could impact the Company's expectations include a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied, including, without limitation, business integration risks; uncertainty of development plans and cost estimates, commodity price fluctuations; political or economic instability and regulatory changes; currency fluctuations, the state of the capital markets, Orpheus' ability to attract and retain qualified personnel and management, potential labour unrest, unpredictable risks and hazards related to the development and operation of exploration programs that are beyond the Company's control, the availability of capital to fund all of the Company's projects. These forward-looking statements are made as of the date of this presentation and the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements, except in accordance with applicable securities laws.